Biotech Knockoffs Lure Novartis
“A big pharma player is expanding its generics business. Expect others to follow
The divide between those making brand-name drugs and those producing generics is about to become a bit less clear. “
Biotech Knockoffs Lure Novartis
“A big pharma player is expanding its generics business. Expect others to follow
The divide between those making brand-name drugs and those producing generics is about to become a bit less clear. “